Loading…
Travere Therapeutics, Inc. is projected to rise to $90.85 by 2027, a +59% move from its current price of $57.28. TVTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $56.33 | $57.31 | $58.31 | +0.06% |
| Aug 2 | $55.96 | $57.35 | $58.77 | +0.11% |
| Aug 3 | $55.68 | $57.38 | $59.12 | +0.17% |
| Aug 4 | $55.46 | $57.41 | $59.43 | +0.23% |
| Aug 5 | $55.26 | $57.44 | $59.71 | +0.28% |
| Aug 6 | $55.09 | $57.48 | $59.96 | +0.34% |
| Aug 7 | $54.93 | $57.51 | $60.20 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $54.93 | $57.51 | $60.20 | +0.40% |
| Week 2 | $54.12 | $57.74 | $61.60 | +0.80% |
| Week 3 | $53.55 | $57.97 | $62.75 | +1.20% |
| Week 4 | $53.10 | $58.20 | $63.78 | +1.60% |
| Week 5 | $52.74 | $58.43 | $64.73 | +2.01% |
| Week 6 | $52.44 | $58.66 | $65.62 | +2.41% |
| Week 7 | $52.18 | $58.90 | $66.48 | +2.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies to people living with rare kidney and metabolic diseases in the United States.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc.
and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Travere Therapeutics, Inc. (TVTX) operates in Healthcare as a biopharmaceutical company focused on therapies for rare kidney and metabolic diseases in the United States. It markets FILSPARI (sparsentan) and Thiola/Thiola EC, with Sparsentan and Pegtibatinase as clinical-stage programs.
The company has a collaboration with PharmaKrysto Limited for cystinuria work and is headquartered in San Diego, California.
A major floor 53.2% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 7.7% above — clearing it would confirm fresh momentum.
Key TVTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $56.56 | Buy | $56.53 | Buy |
| MA 10 | $56.45 | Buy | $56.51 | Buy |
| MA 20 | $56.78 | Buy | $56.17 | Buy |
| MA 50 | $52.81 | Buy | $52.62 | Buy |
| MA 100 | $44.14 | Buy | $46.87 | Buy |
| MA 200 | $38.21 | Buy | $39.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.55 | Neutral |
| Stoch RSI (14) | 62.10 | Neutral |
| CCI (20) | 51.11 | Neutral |
| Williams %R (14) | -3.85 | Info |
| MACD (12,26,9) | -0.37 | Sell |
| ROC (12) | 0.39 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 96.15 | Sell |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.35 | Buy |
| Ultimate (7,14,28) | 55.58 | Neutral |
| Momentum (10) | 2.00 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 56.21 | Buy |
| ADX (14) | 20.44 | Buy |
| ATR (14) | 0.88 | Info |
The 30-day technical picture is bullish, with RSI14 at 60 indicating positive momentum.
Key price levels include SMA50 at $51.49 and SMA200 at $37.44, with immediate support at $46.74 and resistance at $59.03. The stock’s 30-day range runs from $50.86 to $64.69, framing a constructive near-term setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.79 | $57.28 | $79.74 | 0% | Neutral | |
| $74.49 | $90.85 | $115.78 | +59% | Bullish | |
| $87.79 | $109.11 | $142.88 | +90% | Bullish | |
| $100.38 | $126.69 | $169.47 | +121% | Bullish | |
| $119.30 | $152.62 | $207.86 | +166% | Bullish | |
| $127.48 | $165.09 | $228.41 | +188% | Bullish | |
| $146.49 | $191.86 | $269.25 | +235% | Bullish | |
| $183.18 | $242.44 | $344.66 | +323% | Bullish | |
| $210.20 | $280.99 | $404.25 | +391% | Bullish | |
| $243.44 | $328.50 | $477.89 | +474% | Bullish | |
| $385.20 | $542.20 | $826.69 | +847% | Bullish | |
| $747.05 | $1,127.84 | $1,843.53 | +18.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.79 | $57.28 | $66.68 | +0.00% |
| August 2026 | $49.95 | $58.24 | $69.21 | +1.67% |
| September 2026 | $51.44 | $60.32 | $72.36 | +3.58% |
| October 2026 | $51.67 | $60.87 | $73.56 | +0.91% |
| November 2026 | $52.26 | $61.80 | $75.13 | +1.53% |
| December 2026 | $54.98 | $65.24 | $79.74 | +5.56% |
Click any year to see its month-by-month TVTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TVTX is projected to trade between $26.79 and $79.74, averaging $57.28 — a potential gain of 0% from today's $57.28. A consolidation phase looks the most probable path here.
Travere Therapeutics, Inc.'s 2027 outlook centres on $90.85, within a $74.49 to $115.78 range. That is up +59% on the projected 2026 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2028, TVTX could reach as high as $142.88, with a base case around $109.11 and support toward $87.79 — roughly +90% from $57.28. Buyers look set to stay in control over this stretch.
Expect TVTX to range from $100.38 to $169.47 through 2029. The $126.69 average target implies a +121% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The TVTX price prediction for 2030 points to an average of $152.62 (low $119.30, high $207.86) — a potential gain of +166% on today's $57.28. Buyers look set to stay in control over this stretch.
In 2031, TVTX is projected to trade between $127.48 and $228.41, averaging $165.09 — a potential gain of +188% from today's $57.28. That is up +8% on the projected 2030 average. Momentum favours further upside here.
Travere Therapeutics, Inc.'s 2032 outlook centres on $191.86, within a $146.49 to $269.25 range. That is up +16% on the projected 2031 average. That marks a +235% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TVTX could reach as high as $344.66, with a base case around $242.44 and support toward $183.18 — roughly +323% from $57.28. Momentum favours further upside here.
Expect TVTX to range from $210.20 to $404.25 through 2034. The $280.99 average target implies a +391% move from current prices. That is up +16% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TVTX price prediction for 2035 points to an average of $328.50 (low $243.44, high $477.89) — a potential gain of +474% on today's $57.28. Momentum favours further upside here.
In 2040, TVTX is projected to trade between $385.20 and $826.69, averaging $542.20 — a potential gain of +847% from today's $57.28. That is up +65% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Travere Therapeutics, Inc.'s 2050 outlook centres on $1,127.84, within a $747.05 to $1,843.53 range. That is up +108% on the projected 2040 average. That marks a +18.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TVTX today (≈ 17.458101 TVTX) could be worth
$19,689.9
+$18,689.9 (+1869%) by 2050 · US Dollar
Based on the average projected TVTX price of $1,127.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVTXwould be worth at today's price.
$1,000 invested in TVTX on Jul 30, 2025 (≈ 64.599485 TVTX) would be worth
$3,700.26
+$2,700.26 (+270.0%) today · 3.70× · US Dollar
Based on a TVTX entry price of $15.48 vs. today's $57.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $56.68 | $1,010.59 | +1.1% |
| 1 month ago | $56.81 | $1,008.27 | +0.8% |
| 3 months ago | $44.12 | $1,298.28 | +29.8% |
| 6 months ago | $31.09 | $1,842.39 | +84.2% |
| 1 year ago | $15.48 | $3,700.26 | +270.0% |
| All time (5.0y) ago | $14.26 | $4,016.83 | +301.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVTX forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $10.23B
Multiyear forecasts show a strong long-run upside for TVTX, with yearly averages rising substantially into the late 2020s and beyond. The projection for 2026 is an average of $57.36, followed by higher marks in subsequent years.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $118.76, an avg of $151.96, and a max of $207.01 with a ROI of 164.9% and sentiment BULLISH.
Forecasts indicate bullish sentiment across multiple years, with 2027 avg $90.52 (ROI 57.8%), 2028 avg $109.30 (ROI 90.5%), 2030 avg $151.96 (ROI 164.9%), and 2050 avg $1,119.08 (ROI 1851%), but these are estimates, not guarantees.
Yes. The 2030 max is $207.01, which would exceed $200 according to the forecast.
Current price is $57.36 and market cap is $5.33B; the stock is ranked 1225.
2040: avg $535.72, min $380.55, max $816.92; ROI 834%; sentiment BULLISH. 2050: avg $1,119.08, min $741.17, max $1,829.39; ROI 1851%; sentiment BULLISH.
Travere Therapeutics, Inc. Community Discussion
0Share your Travere Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.